Kahn Brothers Group Inc. DE grew its holdings in Pfizer Inc. (NYSE:PFE) by 0.6% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 810,787 shares of the biopharmaceutical company’s stock after purchasing an additional 4,771 shares during the period. Pfizer makes up 3.7% of Kahn Brothers Group Inc. DE’s portfolio, making the stock its 11th biggest position. Kahn Brothers Group Inc. DE’s holdings in Pfizer were worth $29,132,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Morgan Stanley increased its holdings in shares of Pfizer by 2.4% in the second quarter. Morgan Stanley now owns 46,536,777 shares of the biopharmaceutical company’s stock valued at $2,015,972,000 after purchasing an additional 1,071,897 shares in the last quarter. Fisher Asset Management LLC grew its holdings in Pfizer by 2.6% during the 3rd quarter. Fisher Asset Management LLC now owns 45,291,398 shares of the biopharmaceutical company’s stock worth $1,627,320,000 after acquiring an additional 1,158,147 shares during the period. Nuveen Asset Management LLC grew its holdings in Pfizer by 2,240.5% during the 2nd quarter. Nuveen Asset Management LLC now owns 36,086,254 shares of the biopharmaceutical company’s stock worth $1,563,256,000 after acquiring an additional 34,544,423 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in Pfizer by 2.5% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 35,948,881 shares of the biopharmaceutical company’s stock worth $1,557,306,000 after acquiring an additional 868,839 shares during the period. Finally, California Public Employees Retirement System grew its holdings in Pfizer by 5.3% during the 2nd quarter. California Public Employees Retirement System now owns 23,186,244 shares of the biopharmaceutical company’s stock worth $1,004,428,000 after acquiring an additional 1,159,857 shares during the period. Institutional investors own 71.52% of the company’s stock.
A number of equities analysts have recently weighed in on PFE shares. Zacks Investment Research raised shares of Pfizer from a “sell” rating to a “strong-buy” rating and set a $38.00 price target on the stock in a research report on Tuesday, October 1st. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Pfizer in a research report on Tuesday, October 29th. Bank of America started coverage on shares of Pfizer in a research report on Wednesday, October 16th. They set a “neutral” rating and a $37.00 price target on the stock. DZ Bank raised shares of Pfizer from a “sell” rating to a “hold” rating and set a $36.00 price target on the stock in a research report on Wednesday, August 28th. Finally, UBS Group reissued a “neutral” rating and set a $43.00 price target on shares of Pfizer in a research report on Monday, August 5th. Nine investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $44.02.
In other Pfizer news, major shareholder Pfizer Inc purchased 50,000 shares of the stock in a transaction on Tuesday, September 17th. The shares were purchased at an average cost of $18.00 per share, for a total transaction of $900,000.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Scott Gottlieb purchased 3,000 shares of the stock in a transaction on Friday, August 23rd. The stock was acquired at an average price of $34.72 per share, for a total transaction of $104,160.00. Following the completion of the purchase, the director now directly owns 3,000 shares in the company, valued at approximately $104,160. The disclosure for this purchase can be found here. 0.09% of the stock is currently owned by insiders.
PFE traded up $0.14 during trading on Friday, hitting $37.05. The company had a trading volume of 25,261,807 shares, compared to its average volume of 16,850,170. The company has a market capitalization of $207.30 billion, a PE ratio of 12.35, a PEG ratio of 2.11 and a beta of 0.67. Pfizer Inc. has a one year low of $33.97 and a one year high of $46.47. The firm’s 50-day moving average price is $36.61 and its 200 day moving average price is $39.27. The company has a quick ratio of 1.21, a current ratio of 1.47 and a debt-to-equity ratio of 0.60.
Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating the consensus estimate of $0.62 by $0.13. Pfizer had a net margin of 30.57% and a return on equity of 28.61%. The business had revenue of $12.68 billion for the quarter, compared to analysts’ expectations of $12.37 billion. During the same period in the previous year, the firm posted $0.78 EPS. The firm’s revenue was down 4.6% compared to the same quarter last year. Sell-side analysts forecast that Pfizer Inc. will post 2.96 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be paid a $0.36 dividend. The ex-dividend date is Thursday, November 7th. This represents a $1.44 annualized dividend and a yield of 3.89%. Pfizer’s payout ratio is currently 48.00%.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Featured Story: The benefits and drawbacks of dollar cost averaging
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.